Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway is a common signaling pathway used to transduce signals from the extracellular to the intracellular (nucleus) upon the binding of cytokines and growth factors to the extracellular domain of specific cell surface receptors. This signaling pathway is tightly regulated and has a multitude of biological functions such as cell proliferation, differentiation, and apoptosis. Besides, the regulated JAK2/STAT3 signaling plays a crucial role in embryonic development, hemopoiesis, and controlling the immune system. Conversely, aberrantly activated JAK2/STAT3 is frequently detected in varieties of tumors and involved in oncogenesis, angiogenesis, and metastasis of many cancer diseases that are usually refractory to the standard chemotherapy. However, the JAK3/STAT3 pathway recently emerged interestingly as a new site for the development of novel anti-tumor agents and becomes a promising therapeutic target in the treatment of many solid malignancies. Herein, this review aimed to provide insight into the JAK2/STAT3 pathway, in the hope to gain an understanding of its potential role in the pathogenesis, progression, chemotherapy resistance, and cancer therapy of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 1×
“Glioblastoma Glioblastoma, also called glioblastoma multiforme (GBM), is an aggressive type of cancer that starts in the astrocytes of the spinal cord and brain.(114) The JAK2/STAT3 pathway regulates many cellular processes in GBM, for instance, in the survival, proliferation, invasion, anti-apoptosis, and immune evas…”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 2×
“The STAT3 acetylation thus influences tumor growth, DNA methylation, and silencing of the tumor-suppressor gene.(18) Altogether, the JAK2/STAT3 pathway regulates the expression of genes related to cell survival, proliferation, angiogenesis, and immune evasion.”
BackgroundAzevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 1×
“It has been observed that activation of the JAK2/STAT3 pathway is a common mechanism by which inflammation leads to liver carcinogenesis and serves as a potent promoting factor driving liver tumor formation.(87) Particularly, the IL-6/JAK2/STAT3 pathway is aberrantly activated and leads to the dysregulation of downstr…”
BackgroundJAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470 · cited 6×
“Available evidence has documented the involvement of JAK2 in the progression of apoptosis, autophagy, and proliferation of normal cells.(2) It is also responsible for receptor signaling from IL-3 receptor or granulocytemacrophage colony-stimulating factor, both used in hematopoietic cell development.”
BackgroundInfluentialSTAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413 · cited 1×
“Recent studies have shown that STAT3 plays a critical role in KRASdriven pancreatic tumorigenesis as well as in enhancing matrix remodeling and stiffening in pancreatic cancer.(45,46) In the animal model, the STAT3-signaled oncogenic activities inhibit p53 expression, and, in turn, the P53 functional loss or mutation…”
BackgroundSTAT3 is required for Flt3L-dependent dendritic cell differentiation
Laouar, Y., Welte, T., Fu, X.-Y., & Flavell, R. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00332-7 · Cited by 334 · cited 1×
“The JAK2/STAT3 signaling has also been reported to play prominent roles in embryonic development, for instance in the maintenance of the self-renewal capacity of embryonic stem cells and FMS-like tyrosine kinase 3 (Flt3) ligand-dependent dendritic cell (DC) differentiation, as well as in the control of processes such…”
Background
Cited by
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116220 · Cited by 18
Metadata
- Authors
- Mengie Ayele, T., Tilahun Muche, Z., Behaile Teklemariam, A., Bogale, A., & Chekol Abebe, E.
- Venue
- Journal of Inflammation Research
- Publisher
- Informa UK Limited
- Published
- 2022-02
- Volume
- Volume 15
- Pages
- 1349-1364
- ISSN
- 1178-7031 (ISSN-L)
- OpenAlex
- W4213435625
- Cited by
- 213
- References
- 12
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.